Jada Bascom Foundation
All conditions

Leukemias

T-cell prolymphocytic leukemia

Also called: T-PLL · T-cell PLL · T-prolymphocytic leukemia · T-cell chronic lymphocytic leukaemia (historical)

Classified by the World Health Organization as T-cell prolymphocytic leukaemia.

What a donor has to do with this

For some people with this condition, a transplant using blood stem cells from an unrelated donor is part of the treatment guidelines. When a transplant is the right route and no one in the family matches, that donor comes from a registry. Not everyone with this condition has a transplant, and many never need one.

This is our reading of published transplant guidelines for this condition, not a measurement of how many people need a donor. Where a source actually counted donors, the figure and the people it counted are shown further down. Where none did, we say so rather than estimate.

What the evidence says

Who it affects
Typically diagnosed in older adults, with incidence highest from the 70s onward, and is markedly more common in men. Source population/region/year: US SEER cases diagnosed 2001–2020, analyzed in a peer-reviewed study published 2025.
Treatments other than a transplant
Intravenous alemtuzumab is the main first-line treatment; pentostatin- or venetoclax-containing strategies and clinical trials may be used in selected patients, but responses without consolidation are usually short
If a transplant is used, the cells come from
Allogeneic peripheral blood or bone marrow from matched related, matched unrelated, haploidentical or other alternative donors; autologous HCT is reported but is less established; cord-blood use was not reported in the opened disease-specific sources; dominant source not reported in the opened disease-specific sources
How often the donor was unrelated
Not reported. No source we could read states this for this condition, so we do not give a number. An estimate here would be a guess dressed as evidence.

Where this gets complicated

Allo-HCT is the preferred consolidation for eligible responders but has substantial relapse and treatment-related mortality. Auto-HCT appears in consensus discussions yet rests on much smaller evidence and is not equivalent to allo-HCT.

Written for transplant clinicians, not for patients. We quote it so you can see what the guidance actually says:
“Allogeneic hematopoietic cell transplantation is considered the gold standard for this indication”

It describes what teams consider in general. It cannot say what applies to any one person. Read the source.

People with this condition need donors

Joining a registry is a cheek swab and a short health form. You are contacted only if you turn out to be a possible match for someone, and you can ask questions and decline before anything else happens.

Find your registry

Related conditions

Others in leukemias. They are genuinely different diseases with different treatments — the group name is not a diagnosis.

Where this came from